COVID-19 and Severe Asthma: Reflections and Future Solutions [Letter]

Javier Domínguez-Ortega,1,2 Silvia Sánchez-García,3 Carlos Melero Moreno4

1Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; 2CIBER of Respiratory Diseases (CibeRes), Madrid, Spain; 3Department of Allergy, Hospital Infantil Universitario Niño Jesús, Madrid, Spain; 4Instituto de Investigación (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain

Dear editor

On March 14, 2020, the state of emergency was declared in Spain for the management of the COVID-19 healthcare crisis.1 The rapid spread of SARS-CoV-2 generated a state of uncertainty as to what the COVID-19 infection could mean for patients with severe asthma (SA) and as to how to manage the disease in a pandemic scenario.2

In view of the lack of existing knowledge and experience, 12 multidisciplinary healthcare professionals from five different disciplines (pulmonologists, allergists, pediatricians, respiratory specialist nurses and hospital pharmacists) with expertise in SA analyzed the impact of the pandemic situation on SA through the creation of the “Observatory of COVID-19 and Severe Asthma” project. Their objectives were: to analyze the reality of SA management in the COVID-19 setting; to define the specific areas to be addressed in the future; to establish the needs in each area; and to determine the actions to be taken.

We would like to share this model since the pandemic is ongoing and has potential applicability to other clinicians faced with the management of severe asthma during this time.

The panel defined three areas in which immediate action was required and proposed different actions to be implemented and prioritized:

Knowledge About and Research into COVID-19

The need to investigate the impact of lockdown on severe asthma patients; the impact of COVID-19 among the pediatric population;3 and the relationship between socioeconomic status and asthma control and the impact of treatment with biologicals on patients with SA infected with COVID-19 as compared to non-infected patients.4 In this regard, the development of a multidisciplinary database from different hospitals was suggested to perform an in-depth analysis of the impact of COVID-19 on patients with SA.

Information and Education for Patients and Healthcare Professionals

In addition to the need to explain the COVID-19-related guidelines, a lack of in-depth knowledge about asthma was detected. For this reason, the creation of an educational program for patients with severe asthma was proposed, which would cover relevant disease-related aspects and provide tips and advice on the management of everyday life situations, including pandemic-specific recommendations.

The need for digital education focusing on remote care5 was detected, and therefore the creation of informative materials for severe asthma patients intended to help them prepare for remote consultations in advance was recommended.
e-Health
The lockdown called for the implementation of remote consultations and changes at the organizational level. For this reason, the creation of a multidisciplinary intra-hospital coordination document for healthcare professionals involving the management of SA patients was proposed.

The COVID-19 pandemic has brought to light a number of shortcomings that must be addressed: A better understanding of the real impact of SARS-CoV-2 on severe asthma patients; the need for patient education, with the focus on bolstering the more basic concepts; and, perhaps the most significant change, the reduction in face-to-face appointments, leading to standardized remote consultations and e-health approaches.

These conclusions could be applied to any other group of healthcare professionals, and even to other treatment areas, and will impact the future of healthcare, which is currently immersed in far-reaching change and transformation.

Acknowledgments
We would like to thank all the experts in severe asthma for their commitment and dedication who, together with the authors, formed part of the Observatory of COVID-19 and Severe Asthma, without whom this project would not have been possible: Irina Bobolea (Allergology, Hospital Clínic); Carolina Cisneros Serrano (Pneumology, Hospital Universitario La Princesa); David Díaz Pérez (Nursing, Hospital Nuestra Señora de la Candelaria); Noé Garín Escrivá (Hospital Pharmacy, Hospital de la Santa Creu i Sant Pau); Valentin López (Nursing, Hospital Universitario La Paz); Jaime Lozano Blasco (Pediatrics, Hospital Sant Joan de Déu); Xavier Muñoz Gall (Pneumology, Hospital Universitari Vall d’Hebron); Vicente Plaza Moral (Pneumology, Hospital de La Santa Creu i Sant Pau); and Elena Villamañán Bueno (Hospital Pharmacy, Hospital Universitario La Paz). To the GlaxoSmithKline (GSK) team, M Guadalupe Sánchez Herrero, Beatriz Velasco Laorga and Mónica Pantín for their support in carrying out this project and drafting the manuscript. To the strategic consultancy team of Adelphi Targis S.L., comprised of Montse Pérez, Ana Fernández and Nerea Toro for their technical and logistical support.

Funding
This project was supported and funded by GSK for the conducting of the project and medical writing.

Disclosure
Carlos Melero Moreno has received personal fees as a consultant from GSK. Javier Domínguez-Ortega has received fees in the past three years as a consultant and as a speaker at meetings sponsored by ALK-Abeló, AstraZeneca, Chiesi, GSK, LETI, Novartis, Mundipharma, Sanofi and TEVA. Silvia Sánchez-García has received conference fees from GSK, Novartis and Alk-Abelló and financial aid for an AstraZeneca research project. The authors report no other conflicts of interest in this communication.

References